Backed by founding investor Cure Ventures together with The Column Group and AN Venture Partners, Tortugas is headquartered in Framingham, Massachusetts and starts life with four phase 2‑stage small‑molecule programs targeting schizophrenia, tinnitus, focal epilepsy and reversible encephalopathies. Two candidates originate from China’s Jiangsu Hansoh Pharmaceutical Group and two from Japan’s Eisai, all designed as once‑daily oral drugs with “derisked” mechanisms for large, well‑defined CNS indications.

For Nordic stakeholders, the size and quality of this seed/Series A package underscore how quickly capital is returning to neuroscience: a newly formed company with in‑licensed, mid‑stage assets can pull in >100 million USD to fund phase 2 programs, raising the bar for Nordic CNS startups in terms of clinical maturity, indication choice and BD strategy.

This text was partly produced with the help of AI and fact-checked by NLS.